Using a new treatment to reduce inflammation and oxidative stress in acute lung injury
Official title: Targeting inflammation and oxidative stress to treat acute lung injury with CNP-miR146a
Funded at Ceria Therapeutics, INC. · NIH-10930131 · Data updated 2026-11-12
This study is testing a new treatment called CTX-002, which uses tiny particles to help reduce inflammation and stress in the lungs for people with acute lung injury and ARDS, with the hope of improving their recovery and overall health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ceria Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Tucson, UNITED STATES) |
| Project start | April 1, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,216,721 |
| NIH project number | 5R44HL162137-03 |
| Project ID | NIH-10930131 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with acute lung injury or ARDS, particularly those experiencing severe respiratory distress.
✕Less likely to help
Patients with chronic lung diseases or those who do not have acute lung injury may not benefit from this research.
What this research studies
This research focuses on developing a novel therapy, CTX-002, to treat acute lung injury and acute respiratory distress syndrome (ARDS) by targeting inflammation and oxidative stress. The approach involves using cerium oxide nanoparticles that can scavenge reactive oxygen species and reduce inflammation in the lungs. Patients with ARDS often face severe complications, and this treatment aims to improve their outcomes by addressing the underlying causes of lung injury. The research will involve clinical trials to assess the safety and effectiveness of this new therapy.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly improves recovery and survival rates for patients with acute lung injury and ARDS.
How similar studies have gone: While targeting inflammation and oxidative stress in lung injury is a promising approach, this specific treatment using cerium oxide nanoparticles is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Ceria Therapeutics, INC.
Tucson, United States Active
Researchers
- Principal investigator: Jackson, David — Ceria Therapeutics, INC.
- Study coordinator: Jackson, David
Related research
Other NIH-funded projects on the same topics.
-
How vitamin B12 helps the gum-disease bacterium survive
Learning how vitamin B12 helps the bacteria that cause gum disease survive and become more harmful for people with periodontitis.
-
Pancreatic beta cells, oxidative stress, and gestational diabetes
A study is exploring how oxidative stress and changes in pancreatic beta cells during pregnancy may contribute to gestational diabetes and future diabetes risk for both mother and baby.
-
Environmental air pollutants linked to preeclampsia risk in pregnancy
This study looks at whether common air pollutants called PAHs increase the risk of preeclampsia during pregnancy.
-
Oxidative stress and Nlrp3 inflammasome activation in eye lens aging
This grant looks at how aging and oxidative stress drive inflammation in the eye lens, which could help prevent age-related eye diseases.
-
Glyphosate exposure and young adults' metabolic health
A study will look at how glyphosate exposure relates to metabolism and liver health in young adults, using urine measurements and health data.
-
Protein translation control in heart failure under oxidative stress
This project looks at how heart cells manage oxidative stress and how a protein called Nrf2 is produced, which could reveal new ways to help people with heart failure.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.